FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

(NYSE:JNJ) announced today that the FDA granted priority review to a new drug application (NDA) for its TAR-200.

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...

Johnson & Johnson (JNJ) gets FDA priority review for TAR-200 gains, a drug releasing system targeting bladder cancer. Read ...

The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...

Terbinafine or azoles may also prevent the infection reoccurring more than placebo (low-quality evidence). There was probably no significant difference in the risk of adverse events reported when ...

How Lam Stock Can Reach $200 Whereas chip designers such as Nvidia have experienced skyrocketing valuations, Lam's stock has lagged. Shares have decreased by approximately 9% over the past 12 ...

“F1” threads the nitty-gritty details of racing into a traditional underdog drama.

Looking for ASX 200 shares that you can buy and hold forever? Here are three that I think make for great bottom-drawer investments.

UCSF Health said Thursday it is laying off 200 employees systemwide, or about 1% of its workforce, amid “serious financial challenges.” ...

A Central Florida "cat burglar" spoke with News 6 to discuss how she broke into over 200 homes during her criminal escapades.